Moloney Securities Asset Management LLC lifted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 20.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,838 shares of the pharmacy operator's stock after purchasing an additional 5,533 shares during the period. Moloney Securities Asset Management LLC's holdings in CVS Health were worth $2,225,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CVS. Hopwood Financial Services Inc. acquired a new stake in CVS Health in the fourth quarter valued at $29,000. McIlrath & Eck LLC raised its stake in CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 174 shares in the last quarter. Sierra Ocean LLC raised its stake in CVS Health by 584.8% in the first quarter. Sierra Ocean LLC now owns 719 shares of the pharmacy operator's stock valued at $49,000 after buying an additional 614 shares in the last quarter. MV Capital Management Inc. raised its stake in CVS Health by 63.9% in the first quarter. MV Capital Management Inc. now owns 741 shares of the pharmacy operator's stock valued at $50,000 after buying an additional 289 shares in the last quarter. Finally, Dunhill Financial LLC raised its stake in CVS Health by 147.2% in the first quarter. Dunhill Financial LLC now owns 749 shares of the pharmacy operator's stock valued at $51,000 after buying an additional 446 shares in the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.
CVS Health Price Performance
Shares of CVS Health stock traded down $0.98 during trading on Thursday, hitting $65.68. 2,648,099 shares of the company were exchanged, compared to its average volume of 10,784,796. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. CVS Health Corporation has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The stock has a market capitalization of $83.08 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 0.96 and a beta of 0.57. The firm has a 50 day moving average price of $65.18 and a 200 day moving average price of $61.93.
CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the previous year, the firm posted $1.31 EPS. The company's quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.
CVS Health Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.05%. CVS Health's dividend payout ratio (DPR) is presently 63.48%.
Wall Street Analyst Weigh In
A number of analysts have recently commented on CVS shares. Mizuho lifted their target price on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Royal Bank Of Canada raised their price target on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a report on Monday, May 5th. Cowen reissued a "buy" rating on shares of CVS Health in a report on Monday, May 5th. Finally, Jefferies Financial Group raised their price target on CVS Health from $74.00 to $80.00 and gave the stock a "buy" rating in a report on Monday, June 30th. Two research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $75.06.
Get Our Latest Stock Report on CVS
Insiders Place Their Bets
In other CVS Health news, Director Guy P. Sansone purchased 1,570 shares of the business's stock in a transaction on Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director owned 12,007 shares of the company's stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.22% of the company's stock.
About CVS Health
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.